Key result
Rivaroxaban significantly reduced hospital admissions compared to LMWH bridged to warfarin in adult patients with deep vein thrombosis (60% vs 82%; RR 0.73, 95% CI 0.62-0.84).
Why the study?
Does rivaroxaban reduce the rate of hospitalization in adult patients with DVT compared to historical LMWH/warfarin therapy?
Cohort (n=670)
Does rivaroxaban reduce the rate of hospitalization in adult patients with DVT compared to historical LMWH/warfarin therapy?
Relative Risk: 0.73 (95% CI 0.62–0.84)
Absolute Event Rate: 60% vs 82%
The introduction of rivaroxaban for DVT treatment is associated with a significant reduction in hospital admissions compared to traditional LMWH/warfarin bridging therapy.
No takes yet. Share an insight, caveat, or question.
May facilitate outpatient DVT care; leaves open confirmation in randomized trials.
Merli et al. (2015) conducted a cohort in Deep vein thrombosis (n=670). Rivaroxaban vs. Low-molecular-weight heparin (LMWH) bridged to warfarin was evaluated on Rate of hospitalization (RR 0.73, 95% CI 0.62-0.84). Rivaroxaban significantly reduced hospital admissions compared to LMWH bridged to warfarin in adult patients with deep vein thrombosis (60% vs 82%; RR 0.73, 95% CI 0.62-0.84).